DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hemophilia" report to their offering.
The treatment of hemophilia continues to evolve as more long-acting factor concentrates become available, making prophylactic therapy a more feasible approach.
This report addresses the following questions:
What impact will launch timing and duration of action have on the forecasted sales of new long-acting therapies for hemophilia A and hemophilia B?
- What treatments are in development for hemophilia patients with inhibitors?
- How will the emergence of Biogen as a key player in hemophilia impact the market shares of more established companies Bayer, Baxalta, CSL Behring, and Novo Nordisk?
- What impact will the increased usage of prophylactic treatment have on the overall value of the hemophilia market?
- How will the launch of Vonvendi, the first-in-class recombinant von Wille brand factor therapy, change treatment patterns in von Willebrand disease patients?
Key Topics Covered:
FORECAST: HEMOPHILIA
- Executive Summary
- Market Overview and Trends
- Methodology and Market Definition
- Advate
- Adynovate
- Alprolix, 7.BAX 8
- BAY 94-90
- BeneFIX
- CSL6
- Eloctate
- FEIBA
- Idelvion
- Ixinity
- Kogenate/Helixate and Kovaltry
- N8-GP
- N9-GP
- NovoEight
- NovoSeven
- Nuwiq
- Rixubis
- Vonvendi
- Xyntha/ReFacto
- Primary Research Methodology
TREATMENT: HEMOPHILIA
- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Current Treatment Options
- Treatment Dynamics
EPIDEMIOLOGY: HEMOPHILIA
- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast: Hemophilia
- Forecast: Von Willebrand Disease
- Epidemiologist Insight
- Strengths and Limitations
- Appendix
MARKETED DRUGS: HEMOPHILIA
- Executive Summary
- Product Overview
- Products Approved for Acquired Hemophilia
- Products Approved for Von Willebrand Disease
- Appendix
- Product profile: Advate
- Product profile: Adynovate
- Product profile: Alprolix
- Product profile: BeneFIX
- Product profile: Eloctate
- Product profile: FEIBA
- Product profile: Idelvion
- Product profile: Ixinity
- Product profile: Kogenate FS
- Product profile: NovoEight
- Product profile: NovoSeven
- Product profile: Rixubis
- Product profile: Xyntha
PIPELINE: HEMOPHILIA
- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Clinical Trial Design
- Product profile (late stage): BAX 8
- Product profile (late stage): BAY 94-9027
- Product profile (late stage): CSL6
- Product profile (late stage): CSL6
- Product profile (late stage): Kovaltry
- Product profile (late stage): LR7
- Product profile (late stage): N8-GP
- Product profile (late stage): N9-GP
- Product profile (late stage): emicizumab
APPENDIX
- Appendix: Pipeline: Hemophilia
For more information visit http://www.researchandmarkets.com/research/ktb3mx/hemophilia
